“Use With Caution” Isn’t Specific Enough For Labeling, FDA Tells Merck At Vorapaxar Panel
Advisory committee struggles to give a labeling recommendation for lightweight patients, who saw lower efficacy using the platelet inhibitor.
You may also be interested in...
Novel antiplatelet product has suffered from excess bleeding rates in clinical trials and is searching for an appropriate patient population, after initial hopes of being a blockbuster.
Azar says ACIP’s prioritization recommendations should carry weight, but states will be final arbiter of who is vaccinated.
As distribution of Regeneron’s monoclonal antibody treatment for coronavirus begins, OWS officials worry about provider confusion with Lilly’s product due to differences in preparation and administration.